(Q38385856)

English

Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079).

scientific article published on 19 June 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26084990%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079) (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26084990%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26084990%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26084990%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26084990%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26084990%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26084990%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26084990%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Charles Erlichman

11

object named as

C Erlichman

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26084990%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

author name string

B C Goh

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26084990%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

E P Hui

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26084990%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

E H Tan

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26084990%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

G de Lima Lopes

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26084990%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

N R Foster

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26084990%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

M K M Kam

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26084990%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

S F Leung

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26084990%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

K C Chan

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26084990%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

A T C Chan

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26084990%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

publication date

19 June 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26084990%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26084990%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

33

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26084990%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26084990%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

985-991

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26084990%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

https://scigraph.springernature.com/pub.10.1007/s10637-015-0264-0

0 references

Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0264-0

21 January 2018

Prognostic implication of pretreatment plasma/serum concentration of Epstein-Barr virus DNA in nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0264-0

21 January 2018

Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0264-0

21 January 2018

Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0264-0

21 January 2018

A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0264-0

21 January 2018

PIK3CA mutations in nasopharyngeal carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0264-0

21 January 2018

Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0264-0

21 January 2018

Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0264-0

21 January 2018

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0264-0

21 January 2018

Biomarkers of response to Akt inhibitor MK-2206 in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0264-0

21 January 2018

Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0264-0

21 January 2018

Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0264-0

21 January 2018

Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0264-0

21 January 2018

Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0264-0

21 January 2018

PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0264-0

21 January 2018

Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0264-0

21 January 2018

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0264-0

21 January 2018

Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0264-0

21 January 2018

Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0264-0

21 January 2018

Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0264-0

21 January 2018

The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0264-0

21 January 2018

Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0264-0

21 January 2018

Plasma EBV DNA Clearance Rate as a Novel Prognostic Marker for Metastatic/Recurrent Nasopharyngeal Carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0264-0

21 January 2018

Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26084990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26084990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26084990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Expression and significance of PTEN in nasopharyngeal carcinoma]

1 reference

https://pubmed.ncbi.nlm.nih.gov/26084990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/26084990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26084990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genome wide detection of oncogene amplifications in nasopharyngeal carcinoma by array based comparative genomic hybridization

1 reference

https://pubmed.ncbi.nlm.nih.gov/26084990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Screening for mutations in the hotspot mutation regions of PIK3CA gene in nasopharyngeal carcinoma]

1 reference

https://pubmed.ncbi.nlm.nih.gov/26084990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26084990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/26084990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response

1 reference

https://pubmed.ncbi.nlm.nih.gov/26084990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26084990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lung metastasis alone in nasopharyngeal carcinoma: A relatively favorable prognostic group

1 reference

https://pubmed.ncbi.nlm.nih.gov/26084990

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38385856&oldid=1509279595"